Going public

FRAMINGHAM (01/15/2004) - Biotech Immunicon, a developer of cell-based research and diagnostic products for cancer, filed for an initial public offering with the SEC last month. Applying for a Nasdaq listing under the symbol "IMMC," the company stands to raise as much as US$86.2 million, although it did not specify share price or the number of shares it planned to offer in the IPO.